Patents Assigned to Celera Corporation
  • Patent number: 8071291
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: December 6, 2011
    Assignee: Celera Corporation
    Inventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
  • Patent number: 8071302
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: December 6, 2011
    Assignee: Celera Corporation
    Inventor: Hongjin Huang
  • Patent number: 8039212
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: November 4, 2008
    Date of Patent: October 18, 2011
    Assignee: Celera Corporation
    Inventors: Yonghong Li, Hongjin Huang
  • Patent number: 7998689
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: August 16, 2011
    Assignee: Celera Corporation
    Inventors: Elizabeth Joseloff, Steve Ruben, Tao He, Yeounjin Kim
  • Patent number: 7993833
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: August 9, 2011
    Assignee: Celera Corporation
    Inventors: Ann Begovich, Ellen Beasley, Michele Cargill, Steven Schrodi
  • Patent number: 7977052
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular stenosis and MI and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: July 12, 2011
    Assignee: Celera Corporation
    Inventors: May M. Luke, James J. Devlin, Dov Shiffman
  • Patent number: 7960100
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: June 14, 2011
    Assignee: Celera Corporation
    Inventors: Bruno Domon, Aiqun Li, Tao He, Ian McCaffery
  • Patent number: 7947451
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: May 24, 2011
    Assignee: Celera Corporation
    Inventors: Yonghong Li, Ann Begovich, Monica Chang, Michele Cargill, Steven Schrodi
  • Patent number: 7910303
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: March 22, 2011
    Assignees: Celera Corporation, Lieden University Medical Center (LUMC)
    Inventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
  • Patent number: 7892760
    Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: February 22, 2011
    Assignee: Celera Corporation
    Inventors: Charles Birse, Marcia Lewis, Steve Ruben, Mehdi Mesri
  • Patent number: 7863021
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: January 4, 2011
    Assignee: Celera Corporation
    Inventors: Steven J. Schrodi, Ann B. Bogovich
  • Patent number: 7842291
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Paul A. Moore, Tao He, Candy N. Lee, Karen Van Orden, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
  • Patent number: 7842466
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Yeounjin Kim, Tao He, Steve Ruben
  • Patent number: 7842467
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with breast. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in breast diseases (BCAT) and antibodies binds to BCAT. The present invention provides that BCAT is used as targets for screening agents that modulates the BCAT activities. Further the present invention provides methods for treating diseases associated with breast.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Jenny Heidbrink, Steve Ruben, Charles E. Birse, Tao He
  • Patent number: 7833706
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: November 16, 2010
    Assignee: Celera Corporation
    Inventors: Ann Bethea Begovich, Victoria Elizabeth Hope Carlton, Steven Jon Schrodi, Heather Camille Alexander
  • Patent number: 7820380
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: October 26, 2010
    Assignee: Celera Corporation
    Inventor: Hongjin Huang
  • Patent number: 7816083
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: October 19, 2010
    Assignee: Celera Corporation
    Inventors: Andrew Grupe, Yonghong Li
  • Patent number: 7811794
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: October 12, 2010
    Assignee: Celera Corporation
    Inventors: Michele Cargill, Ann Bethea Begovich, Heather Camille Alexander
  • Patent number: 7807392
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung cancer (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: October 5, 2010
    Assignee: Celera Corporation
    Inventors: Bruno Domon, Elizabeth Joseloff, Aiqun Li, Tao He
  • Patent number: 7799530
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: September 21, 2010
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James Devlin